Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (6)

2023

  1. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072

2022

  1. Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 11, pp. 3293-3308

2021

  1. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs

    European Respiratory Journal

2019

  1. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 5, pp. 1418-1429

2018

  1. The prostaglandin D 2 receptor 2 pathway in asthma: A key player in airway inflammation 11 Medical and Health Sciences 1107 Immunology 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

    Respiratory Research, Vol. 19, Núm. 1

2001

  1. An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors

    European Journal of Neuroscience, Vol. 13, Núm. 8, pp. 1469-1478